Search research articles
Contact Us
Filters
Showing results (21-30 of 50) with videos related to
Page
of 5
Sort By:
British Journal of Haematology
|
November 19, 2016
The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF)
Ruben Mesa, Alessandro M Vannucchi, Abdulraheem Yacoub, et al.
Ejhaem
|
March 20, 2025
Safety and Efficacy of Busulphan Based on Dosing Patterns in the Real-World Management of Myeloproliferative Neoplasms
Ali Mahdi, Alexandros Rampotas, Patrick Roberts, et al.
British Journal of Haematology
|
January 3, 2024
Real-world efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis
Jahanzaib Khwaja, Joshua Bomsztyk, Maria Atta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 6, 2020
Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial
Meletios A Dimopoulos, Ivan Špička, Hang Quach, et al.
Blood Advances
|
February 22, 2024
Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia
David J Kuter, Jiri Mayer, Merlin Efraim, et al.
American Journal of Hematology
|
January 23, 2025
Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study
Nichola Cooper, A J Gerard Jansen, Robert Bird, et al.
Therapeutic Advances in Hematology
|
April 4, 2022
A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study
Adam J Mead, Nauman M Butt, Waseem Nagi, et al.
Haematologica
|
April 29, 2021
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK<i>five</i>)
Kwee L Yong, Samantha Hinsley, Holger W Auner, et al.
The Lancet. Haematology
|
September 9, 2024
Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial
Gordon Cook, A John Ashcroft, Ethan Senior, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 14, 2023
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma
Martin F Kaiser, Andrew Hall, Katrina Walker, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 50) with videos related to
Sort By:
Page
of 5
British Journal of Haematology
|
November 19, 2016
The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF)
Ruben Mesa, Alessandro M Vannucchi, Abdulraheem Yacoub, et al.
Ejhaem
|
March 20, 2025
Safety and Efficacy of Busulphan Based on Dosing Patterns in the Real-World Management of Myeloproliferative Neoplasms
Ali Mahdi, Alexandros Rampotas, Patrick Roberts, et al.
British Journal of Haematology
|
January 3, 2024
Real-world efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis
Jahanzaib Khwaja, Joshua Bomsztyk, Maria Atta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 6, 2020
Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial
Meletios A Dimopoulos, Ivan Špička, Hang Quach, et al.
Blood Advances
|
February 22, 2024
Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia
David J Kuter, Jiri Mayer, Merlin Efraim, et al.
American Journal of Hematology
|
January 23, 2025
Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study
Nichola Cooper, A J Gerard Jansen, Robert Bird, et al.
Therapeutic Advances in Hematology
|
April 4, 2022
A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study
Adam J Mead, Nauman M Butt, Waseem Nagi, et al.
Haematologica
|
April 29, 2021
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK<i>five</i>)
Kwee L Yong, Samantha Hinsley, Holger W Auner, et al.
The Lancet. Haematology
|
September 9, 2024
Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial
Gordon Cook, A John Ashcroft, Ethan Senior, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 14, 2023
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma
Martin F Kaiser, Andrew Hall, Katrina Walker, et al.
Page
of 5